Sangamo Therapeutics, Inc.
NASDAQ:SGMOBiotechnology
+$0.00 today
- Market cap
- $70.43M
- Beta
- 1.29
- P/E (TTM)
- -0.5
- EPS (TTM)
- -$0.32
Volume 0.61M
Average 9.53M
SGMO Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Sangamo Therapeutics, Inc.NASDAQ: SGMO
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $877K fell 54.4% year over year, behind the -25.2% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 53.4% from the prior quarter. Over 3 fiscal years it compounded at -28.2% a year.
Context
- Depreciation & amortization amounted to 19.2% of revenue in FY2025, up 3.0 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -54.4% toward the trailing-twelve-month pace of -25.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 7.6M USD
- Year-over-year change
- -18.8%
- 4-year CAGR
- -19.0%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 7.6M | -18.8% |
| FY2024 | 2024-12-31 | 9.36M | -57.8% |
| FY2023 | 2023-12-31 | 22.19M | +7.9% |
| FY2022 | 2022-12-31 | 20.56M | +16.6% |
| FY2021 | 2021-12-31 | 17.64M | — |
Depreciation & Amortization vs competitors
How SGMO compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -25.2% is the 10th highest of 11, against a peer median of +26.1%.
- Depreciation & amortization amounts to 19.0% of revenue for SGMO, versus a peer median of 25.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $23.65M USD | +1.1% | +6.0% | 81.8% | |
| LTM Mar 2026 | $6.75M USD | +171.1% | -20.0% | 8.6% | |
| LTM Mar 2026 | $6.56M USD | -25.2% | -28.2% | 19.0% | |
| FY2025 | €5.09M EUR | +155.3% | -51.8% | 182.7% | |
| LTM Mar 2026 | $3.38M USD | +84.9% | +5.3% | 9.7% | |
| LTM Mar 2026 | CHF 2.37M CHF | +2.1% | -3.5% | — | |
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | $2.34M USD | +35.9% | -25.1% | 119.9% |
| LTM Mar 2026 | $1.88M USD | -43.4% | +65.8% | 3.4% | |
| LTM Mar 2026 | $1.61M USD | +16.3% | +19.7% | 54.5% | |
| LTM Mar 2026 | $810K USD | -21.4% | +18.0% | 25.6% | |
| LTM Mar 2026 | $143K USD | +37.5% | +8.6% | 8.0% | |
| Peer median (excluding SGMO) | — | +26.1% | +5.7% | 25.6% | |
Competitors are the stored peer set for SGMO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (178.3M) | (192.28M) | (257.83M) | (97.94M) | (122.93M) |
| Depreciation & Amortization | 17.64M | 20.56M | 22.19M | 9.36M | 7.6M |
| Deferred Income Tax | 2.77M | 0 | (6.34M) | 0 | 0 |
| Stock-Based Compensation | 32.96M | 31.65M | 27.36M | 12.38M | 9.08M |
| Change in Working Capital | (101.9M) | (82.32M) | (164.03M) | 4.51M | (4.22M) |
| Accounts Receivables | (789K) | 2.34M | (976K) | 953K | 155K |
| Inventory | 7.66M | 0 | 0 | 0 | 0 |
| Accounts Payables | (7.66M) | 13.35M | 5.59M | (14.17M) | 2.79M |
| Other Working Capital | (101.11M) | (98M) | (168.65M) | 17.72M | (7.17M) |
| Other Non-Cash Items | (6.43M) | (1.24M) | 153.8M | 4.55M | 13.27M |
| Operating Cash Flow | (233.25M) | (223.63M) | (224.84M) | (67.14M) | (97.21M) |
| Capital Expenditures | (23.28M) | (20.17M) | (21.16M) | (267K) | (102K) |
| Acquisitions (Net) | (119K) | (79.46M) | 0 | 1.95M | 0 |
| Purchases of Investments | (338.16M) | (277.39M) | (59.55M) | 0 | 0 |
| Sales of Investments | 609.76M | 356.85M | 234.24M | 35.84M | 0 |
| Other Investing Activities | 0 | 79.46M | 0 | 0 | 0 |
| Investing Cash Flow | 248.2M | 59.29M | 153.53M | 37.52M | (102K) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 27.1M | 84.87M | 15.11M | 28.99M | 74.01M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 5.76M | (209K) | (518K) | (614K) | (3.26M) |
| Financing Cash Flow | 32.86M | 84.66M | 14.59M | 28.38M | 70.75M |
| Effect of Forex Changes | (263K) | 1.25M | 1.48M | (2.05M) | 4.09M |
| Net Change in Cash | 47.54M | (78.43M) | (55.24M) | (3.29M) | (22.47M) |
| Free Cash Flow | (256.53M) | (243.8M) | (246M) | (67.41M) | (97.31M) |
Sangamo Therapeutics, Inc.
NASDAQ:SGMO
Intrinsic Alpha fair value
Locked
Current Price
$0.18
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.